Psoriatic Arthritis- Secondary Care

Similar documents
Psoriatic Arthritis- Second Line Treatments

Otezla. Otezla (apremilast) Description

Psoriatic arthritis FACTSHEET

Cimzia. Cimzia (certolizumab pegol) Description

Cosentyx. Cosentyx (secukinumab) Description

A Patient s Guide to. Treatments for Psoriatic Arthritis

Stelara. Stelara (ustekinumab) Description

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)

Helpline No:

Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases

CIMZIA (certolizumab pegol)

RHEUMATOID ARTHRITIS DRUGS

1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.

Regulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)

Xeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

Abatacept Drug information. Abatacept is used to treat rheumatoid arthritis.

Stelara. Stelara (ustekinumab) Description

Methotrexate for inflammatory bowel disease: what you need to know

Drug information. Apremilast APREMILAST. is used to treat psoriasis and psoriatic arthritis. Helpline

Regulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)

Horizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330

INFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)

Abatacept. What is abatacept?

Biologic Immunomodulators Prior Authorization with Quantity Limit Program Summary

Ciclosporin. Drug information. Ciclosporin is used to treat rheumatoid arthritis, lupus, psoriatic arthritis and other conditions.

apremilast 10mg, 20mg, 30mg tablets (Otezla ) SMC No. (1053/15) Celgene Ltd.

Infliximab Drug information. Infliximab can treat rheumatoid arthritis and psoriatic arthritis.

ACTEMRA (tocilizumab)

Medication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013

Corporate Medical Policy

Guidelines for rheumatology patients on biologic therapy. Rheumatology Department Patient Information Leaflet

Certolizumab pegol (Cimzia) for psoriatic arthritis second line

Clinical Policy: Abatacept (Orencia) Reference Number: ERX.SPA.123 Effective Date:

MEDICATION GUIDE. (tocilizumab)

Corporate Medical Policy

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Psoriatic Arthritis (PsA) P&T DATE 2/15/2018 CLASS:

Public observer slides

Biologics for Autoimmune Diseases

Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS

Tocilizumab Tocilizumab

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

First Name. Specialty: Fax. First Name DOB: Duration:

Center for Evidence-based Policy

Seronegative Arthritis. Dr Mary Gayed 25 th April 2018

Why have I been selected for treatment with adalimumab?

Medication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014

Azathioprine. Drug information. Azathioprine is used to treat rheumatoid arthritis, lupus and other conditions.

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

KEEP UP THE FIGHT WITH. Little Victories

Cimzia. Cimzia (certolizumab pegol) Description

COSENTYX (secukinumab)

2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients

Ustekinumab is used to treat moderate to severe plaque psoriasis in adults. Why have I been selected for treatment with ustekinumab?

Anti-Tumor Necrosis Factor (Anti-TNF)

Dr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru

Regulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)

Pharmacological Management of Knee Pain

Drug information. Secukinumab SECUKINUMAB. is used to treat psoriatic arthritis and ankylosing spondylitis. Helpline

WHAT YOU SHOULD KNOW ABOUT RoACTEMRA

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

Horizon Scanning Centre January Apremilast for psoriatic arthritis SUMMARY NIHR HSC ID: 3716

Pharmacy Management Drug Policy

USTEKINUMAB Generic Brand HICL GCN Exception/Other USTEKINUMAB STELARA GUIDELINES FOR USE

certolizumab pegol (Cimzia )

Actemra. Actemra (tocilizumab) Description

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life. Edition 4

Clinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: Last Review Date: Line of Business: HIM, Medicaid

BACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.

Drug information. Sarilumab SARILUMAB. is used to treat rheumatoid arthritis. Helpline

Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)

Package leaflet: Information for the patient

Psoriasis. and Biologic Treatments. Choose the best treatment to regain your quality of life.

Information about... Infliximab. Ophthalmology Service Scottish Uveitis National Managed Clinical Network

Cimzia. Cimzia (certolizumab pegol) Description

MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)

ETANERCEPT Generic Brand HICL GCN Exception/Other ETANERCEPT ENBREL GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

2017 Blue Cross and Blue Shield of Louisiana

Drug Class Review Targeted Immune Modulators

o Your healthcare provider should test you for TB before starting CIMZIA.

1. Does the patient have a diagnosis of moderate to severe polyarticular juvenile idiopathic arthritis (PJIA)?

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

Get an Insurance Benefits Review for ORENCIA (abatacept)

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process

TOFACITINIB PATIENT INFORMATION ON. (Brand name: Xeljanz ) What is tofacitinib? Important things to remember

Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria

Rheumatoid Arthritis Fact Sheet

Why is this important for you? Types of arthritis. Information for the public Published: 28 February 2017 nice.org.uk

Therapeutic Agents in Rheumatic and Inflammatory Diseases Drug Class Prior Authorization Protocol

Fml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.

Appendix 1: Frequently Asked Questions

3 rd Appraisal Committee meeting, 28 February 2017 Committee D

Drugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending

Regulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:

Drug information. Baricitinib BARICITINIB. is used to treat rheumatoid arthritis. Helpline

Perioperative Medicine:

Transcription:

Psoriatic Arthritis- Secondary Care Our Psoriatic Arthritis: First Line Treatments information sheet gives information on the treatments that can be prescribed by a GP, or that might be prescribed if the psoriatic arthritis is only present in one joint, or not getting worse. Most people with psoriasis should be referred to a Rheumatologist (a hospital consultant that specialises in arthritis) as soon as psoriatic arthritis is suspected. There is no straightforward test to diagnose psoriatic arthritis, and so a Rheumatologist is best placed to confirm a diagnosis, and give advice on treatment options. This information sheet covers Disease Modifying Anti Rheumatic Drugs (DMARDs). These treatments cannot be prescribed by a GP, and are usually prescribed by a Rheumatologist, Dermatologist, or in a combined clinic where both the Dermatologist and Rheumatologist are present. The DMARD category for psoriatic arthritis includes: Methotrexate Sulfasalazine Leflunomide Apremilast Biologic treatments Cimzia (certolizumab pegol), Cosentyx (secukinumab), Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi (golimumab), Stelara (ustekinumab) 1 What are DMARDs? DMARDs are treatments that alter the condition itself, rather than just treat the symptoms. DMARDs work by attacking the causes of inflammation in the joints. They lessen the activity of arthritis by reducing swelling and stiffness, reducing the pain as well. These treatments are different to anti-inflammatory medications, as they can help to stop the arthritis from getting any worse. It can take a number of months for a DMARD to reach its full effect. However, they can often be taken at the same time as other first line medications, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and painkillers, to help ease symptoms whilst the DMARD begins to work. Most DMARDs work on the immune system and are designed to be taken long-term, and therefore there is a possibility of more significant side effects than with painkillers and NSAIDs alone.

When should DMARDs be prescribed? Psoriatic arthritis can cause irreversible damage to joints if effective DMARD treatment is not given when appropriate. There are two categories of DMARDs that are used for psoriatic arthritis traditional systemics, and the newer biologic treatments. Traditional systemic DMARDs (such as methotrexate, sulfasalazine, leflunomide) should be considered if: There is active psoriatic arthritis (i.e. inflammation is present in several joints despite using NSAIDs) The individual is unable to go about daily living, work or recreation easily Many joints are affected. Biologic Treatments should be considered if: The person has arthritis with three or more joints that are tender to touch and three or more joints that look or feel swollen, and at least two other traditional systemic DMARDs haven t worked or cannot be tolerated (ie. caused side effects that meant treatment had to be stopped). As with psoriasis, it is often a process of trial and error to find a treatment or combination of treatments that work well for each person with psoriatic arthritis. Because of this, a second biologic treatment should be tried if no acceptable improvement is seen after 12 weeks on an initial biologic. 2 The following is a brief summary of some of the commonly-prescribed DMARDs for psoriatic arthritis. You should always check with your doctor before taking any other medications (including vitamins or herbal supplements) whilst you are being prescribed any of the DMARDs below. Similarly, you should always ask your doctor for advice on drinking alcohol, getting pregnant or breastfeeding whilst taking one of these treatments. Further information on each of these treatments is available from the Psoriasis Association. Methotrexate (also referred to by its commercial names Matrex or Ebetrex) Methotrexate works to suppress the overactive immune system which causes inflammation, swelling and stiffness in psoriatic arthritis. Because of this suppression, a person taking methotrexate is likely to be more prone to infections. Methotrexate is usually taken in tablet form once a week, but in some cases it is given as an injection. It can take up to 12 weeks to become fully effective. People taking methotrexate will need regular blood tests to monitor liver and bone marrow function, and check for infections. They should also have an annual flu vaccination.

Methotrexate can also be used to treat psoriasis please see our Methotrexate information sheet for more in-depth information on this treatment. Sulfasalazine (also referred to by its commercial name Salazopyrin) Sulfasalazine reduces inflammation in the joints, and decreases pain, swelling and stiffness. Some people will start to notice results within a few weeks of starting the treatment, however, it may take around 12 weeks for sulfasalazine to have a full effect. Sulfasalazine is a tablet that is usually taken every day. The number and time to take your tablet will be explained to you by your doctor. The tablet has a special coating which means it dissolves more slowly, passing beyond the stomach before releasing its contents. This can help reduce nausea and stomach irritation associated with other treatments. You will need to have frequent blood tests for the first three months of taking the drug, followed by regular tests every three months, to monitor liver function and check for infections. You may also need an annual flu vaccination. Sulfasalazine may also turn your urine orange or dark yellow and your tears may be discoloured. This is nothing to worry about, however if you use extended wear contact lenses tell your doctor as they may develop an orange stain. Leflunomide (also referred to by its commercial name Arava) Leflunomide, like methotrexate was initially developed for use in the treatment of cancer. Leflunomide is an anti-t cell medication and as such is thought to control inflammation by interfering with T cell production of cytokines, similar to some of the biologics. It acts to suppress the overactive immune system, causing damage and pain to the joints. 3 Leflunomide is a tablet that is taken every day. Like other DMARDs, leflunomide does not work immediately it may be up to six weeks before you feel any effect and as long as six months before you feel the full benefit. The potential side effects of leflunomide are similar to methotrexate and so you will have regular blood and blood pressure tests, and may need an annual flu vaccination. Apremilast (also referred to by its commercial name Otezla) It is not known exactly how Otezla works in psoriasis or psoriatic arthritis. However, it is known that Otezla inhibits (ie. stops it from working as it usually does) an enzyme known as phosphodiesterase 4, or PDE4. PDE4 controls the inflammatory action within a cell, which can affect the level of inflammation associated with psoriasis or psoriatic arthritis. Helping to control this inflammation can lead to an improvement in symptoms for people with psoriasis or psoriatic arthritis.

Otezla is taken orally in tablet form twice a day. The dose is gradually increased over the first five days, until the patient is taking the full 30mg twice a day from day six onwards. Again, you will have regular monitoring tests, and may need an annual flu vaccination. Most people will need to have tried two of the more traditional systemic DMARDs before they can be offered apremilast to treat their psoriatic arthritis. Biologic Treatments A number of biologic treatments are available to treat psoriatic arthritis. There are various criteria for when biologic treatments can be prescribed to treat psoriatic arthritis, and for some treatments the criteria may vary if you are in Scotland compared to England or Wales. Please check the information sheet on each individual biologic treatment for more information about when it can be prescribed. The following treatments work in similar ways by suppressing a specific chemical called tumour necrosis factor-alpha (TNF-alpha) that is involved in triggering inflammation in the immune system. Cimzia is taken in two injections at weeks 0, 2 and 4, and then in one injection every two weeks. Treatment may be stopped if no significant results are seen within 12 weeks. Enbrel is usually taken once or twice a week by injection. Again, treatment may be stopped if no significant results are seen within 12 weeks. Humira is usually taken once every two weeks by injection. Again, treatment may be stopped if no significant results are seen within 12 weeks. Remicade is given in hospital using an intravenous drip into a vein (an infusion). Initially the infusions are given once at the beginning of treatment, after two weeks, and then after another four weeks. You will then need an infusion (which takes between one and two hours) every eight weeks. Again, treatment may be stopped if no significant results are seen within 12 weeks. Simponi is taken once a month by injection, on the same date each month. Again, treatment may be stopped if no significant results are seen within 12 weeks. 4 Stelara works in a slightly different way by slowing down the activity of interleukin 12 (IL-12) and interleukin 23 (IL-23), chemical messengers in the immune system that signal other cells to cause inflammation. It is usually taken by injection at week 0, week 4, and then every 12 weeks after that. Treatment may be stopped if no significant results are seen within 24 weeks. Cosentyx and Taltz also work on interleukin activity they bind to interleukin 17A (IL-17A) to inhibit (ie. stop it from working as it usually does) its inflammatory action. Cosentyx usually taken by two injections given at the same time, weekly for the first four weeks, and then every four weeks after that. Taltz is taken every other week until week 12, and then every four weeks after that.

As with the traditional systemic DMARDs, people taking biologic treatments will have regular blood tests and other checks, to monitor for side effects. As biologic treatments suppress the immune system, it is recommended that people taking them have an annual flu vaccination, as well as a pneumococcal vaccination before you start biologic treatment. Not all vaccinations, however, are safe to have when taking a biologic treatment, so you should always check with your Rheumatologist or another healthcare professional before having them. This is not a complete list of the second line treatments a Rheumatologist may prescribe for you; other treatments that are usually used for other forms of inflammatory arthritis may be prescribed on a case-by-case basis. More in-depth information on the treatments featured in this resource, and on first line treatments for psoriatic arthritis, is available from the Psoriasis Association. The information in this resource is not intended to replace that of a healthcare professional: If you have any concerns or questions about your treatment, do discuss this with your doctor and always read the patient information leaflet to make sure you are using them correctly. For more information, or for a list of resources used in the production of this information sheet, please contact the Psoriasis Association. 5 August 2018 (Review Date: 12/20)